Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- EyePoint Pharmaceuticals, Inc.
- Study ID
- NCT05381948
- Phase
- PHASE2
- Status
- Completed
Conditions
- Wet Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- EYP-1901 — DRUGIntravitreal Injection
- Aflibercept 2mg/0.05mL Inj,Oph — DRUGIntravitreal Injection
Study Details
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
Key Dates
- Start date
- Jun 30, 2022
- Status verified
- Oct 2025
- Primary completion
- Nov 29, 2023
- Completion
- Apr 24, 2024
Study Design
- Enrollment
- 161 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: EYP-1901 2060 mcgEYP-1901 2060 mcg, single dose
- Experimental: EYP-1901 3090 mcgEYP-1901 3090 mcg, single dose
- Active Comparator: AfliberceptAflibercept 2 milligram (mg) \[0.05 milliliter (mL)\] every 8 weeks
Primary Outcome Measure
Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32 [ Time Frame: Baseline (Day 1) and Weeks 28 and 32 ]
Locations (67)
Related coverage on Hipa.ai
- EYP-1901 for wAMD Shows Comparable Visual Acuity Changes to AfliberceptEYP-1901 · Oct 2, 2025 · ClinicalTrials.gov
Find similar trials in Phoenix, AZ
Related Studies
- MMP-9 Inhibition for Recalcitrant Wet AMDPHASE2 · Recruiting · University of Iowa · Iowa City, Iowa
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDPHASE3 · Recruiting · AbbVie · Phoenix, Arizona